<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02717052</url>
  </required_header>
  <id_info>
    <org_study_id>1643/2014</org_study_id>
    <secondary_id>2014-003280-38</secondary_id>
    <nct_id>NCT02717052</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography Assessment of Ketamine Binding of the Serotonin Transporter</brief_title>
  <official_title>Positron Emission Tomography Assessment of Ketamine Binding of the Serotonin Transporter and Its Relevance for Rapid Antidepressant Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <brief_summary>
    <textblock>
      The study at hand is the first to investigate ketamine's SERT binding in humans, by utilizing
      the highly selective SERT radioligand [11C]DASB and positron emission tomography.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravenous application of ketamine is currently dramatically gaining in significance as a
      rapid and highly effective antidepressant treatment option. Ketamine modulates various
      neurotransmitter systems, though the mechanisms responsible for its antidepressant effects
      remain unkownn. However, the serotonin transporter (SERT) presents a target of high interest
      due to the SERT's fundamental role in depression's pathophysiology as well as in
      antidepressant response. The study at hand is the first to investigate ketamine's SERT
      binding in humans, by utilizing the highly selective SERT radioligand [11C]DASB and positron
      emission tomography. Further, investigation of severely depressed patients provides the
      unique opportunity to establish the relationship between ketamine's SERT binding and its
      antidepressant efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Pilot I and Pilot III not randomised</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pilot Study II: (S)-ketamine SERT occupancy assessed with DASB binding potential (BP)</measure>
    <time_frame>during PET/during 135 minutes of infusion</time_frame>
    <description>Occupancy assessed using kinetic modeling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pilot Study II: (R,S)-ketamine SERT occupancy assessed with DASB binding potential (BP)</measure>
    <time_frame>during PET/during 135 minutes of infusion</time_frame>
    <description>Occupancy assessed using kinetic modeling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Main Study: (S)-ketamine SERT occupancy assessed with DASB binding potential (BP)</measure>
    <time_frame>during PET/starting 10 minutes afer 40 minutes of infusion</time_frame>
    <description>Occupancy (%)=(1−BPND PET 2 (treatment) / BPND PET 1 (baseline)) x100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pilot Study I: (R,S)-ketamine SERT occupancy assessed with DASB binding potential (BP)</measure>
    <time_frame>during PET/starting 10 minutes afer 40 minutes of infusion</time_frame>
    <description>Occupancy (%)=(1−BPND PET 2 (treatment) / BPND PET 1 (baseline)) x100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pilot Study III: (R,S)-ketamine SERT occupancy assessed with DASB binding potential (BP)</measure>
    <time_frame>during PET</time_frame>
    <description>Occupancy (%)=(1−BPND PET 2 (treatment) / BPND PET 1 (baseline)) x100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pilot Study III: resting state MRI</measure>
    <time_frame>after PET 2</time_frame>
    <description>changes to rsFC and rsfMRI after (R,S)-ketamine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pilot Study III: MRS</measure>
    <time_frame>after PET 2</time_frame>
    <description>changes to Glutamate, GABA, and metabolites after (R,S)-ketami</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton Depression Rating Scale Points</measure>
    <time_frame>2 hours after infusion to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton Depression Rating Scale Points</measure>
    <time_frame>1 day after infusion to baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Depression</condition>
  <condition>Ketamine</condition>
  <arm_group>
    <arm_group_label>(S)-ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH
Dosis: 0.25mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)
all patients and 10 HC (randomized, double blind)
Interventions:
Drug: (S)-ketamine (Main study) Other: Main study: PET1 Other: Main study: PET2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)
10 HC (randomized, double blind)
Interventions:
Drug: Placebo Other: Main study: PET1 Other: Main study: PET2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(S)-ketamine (Pilot Study II, 5 subj.)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH
Dosis: 0.10mg/kg bodyweight bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.30mg/kg bodyweight applied over the course of 130 minutes.
Pilot-study II is cross-over design!
Interventions:
Drug: (S)-ketamine (Pilot II) Other: PILOT Study II: PET1 Other: PILOT Study II: PET2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(R,S)-ketamine (Pilot Study II, 5 subj.)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma
Dosis: 0.20mg/kg bodyweight bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.60mg/kg bodyweight applied over the course of 130 minutes.
Pilot-study II is cross-over design!
Interventions:
Drug: (R,S)-ketamine (Pilot II) Other: PILOT Study II: PET1 Other: PILOT Study II: PET2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(R,S)-ketamine (Pilot Study I, 12 subj.)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma
Dosis: 0.50mg/kg bodyweight i.v. over 40 Minutes (ending 5 minutes before PET measurement)
Interventions:
Drug: (R,S)-ketamine (Pilot I) Other: PILOT Study I: PET1 Other: PILOT Study I: PET2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(R,S)-ketamine (Pilot Study III, 12 subj.)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma
Dosis: 0.80mg/kg bodyweight i.v. over 50 Minutes
Interventions:
Drug: (R,S)-ketamine (Pilot III) Other: PILOT Study III: PET1 Other: PILOT Study III: PET2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(S)-ketamine (Main study)</intervention_name>
    <description>Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH
Dosis: 0.25mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)</description>
    <arm_group_label>(S)-ketamine</arm_group_label>
    <other_name>Esketaminhydrochlorid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(S)-ketamine (Pilot II)</intervention_name>
    <description>Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH
Dosis: 0.10mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.30mg/kg bodyweight i.v. applied over the course of 130 minutes.</description>
    <arm_group_label>(S)-ketamine (Pilot Study II, 5 subj.)</arm_group_label>
    <other_name>Esketaminhydrochlorid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(R,S)-ketamine (Pilot II)</intervention_name>
    <description>Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma
Dosis: 0.20mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.60mg/kg bodyweight applied i.v. over the course of 130 minutes.</description>
    <arm_group_label>(R,S)-ketamine (Pilot Study II, 5 subj.)</arm_group_label>
    <other_name>Ketaminhydrochlorid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PILOT Study II: PET1</intervention_name>
    <description>[11C]DASB PET</description>
    <arm_group_label>(S)-ketamine (Pilot Study II, 5 subj.)</arm_group_label>
    <arm_group_label>(R,S)-ketamine (Pilot Study II, 5 subj.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PILOT Study II: PET2</intervention_name>
    <description>[11C]DASB PET</description>
    <arm_group_label>(S)-ketamine (Pilot Study II, 5 subj.)</arm_group_label>
    <arm_group_label>(R,S)-ketamine (Pilot Study II, 5 subj.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Main Study: PET1</intervention_name>
    <description>[11C]DASB PET</description>
    <arm_group_label>(S)-ketamine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Main Study: PET2</intervention_name>
    <description>[11C]DASB PET</description>
    <arm_group_label>(S)-ketamine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PILOT Study I: PET1</intervention_name>
    <description>[11C]DASB PET</description>
    <arm_group_label>(R,S)-ketamine (Pilot Study I, 12 subj.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PILOT Study I: PET2</intervention_name>
    <description>[11C]DASB PET</description>
    <arm_group_label>(R,S)-ketamine (Pilot Study I, 12 subj.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(R,S)-ketamine (Pilot I)</intervention_name>
    <description>Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma
Dosis: 0.50mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)</description>
    <arm_group_label>(R,S)-ketamine (Pilot Study I, 12 subj.)</arm_group_label>
    <other_name>Ketaminhydrochlorid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(R,S)-ketamine (Pilot III)</intervention_name>
    <description>Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma
Dosis: 0.80mg/kg bodyweight i.v. over 50</description>
    <arm_group_label>(R,S)-ketamine (Pilot Study III, 12 subj.)</arm_group_label>
    <other_name>Ketaminhydrochlorid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PILOT Study III: PET1</intervention_name>
    <description>[11C]DASB PET</description>
    <arm_group_label>(R,S)-ketamine (Pilot Study III, 12 subj.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PILOT Study III: PET2</intervention_name>
    <description>[11C]DASB PET</description>
    <arm_group_label>(R,S)-ketamine (Pilot Study III, 12 subj.)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-55 years

          -  somatic health

          -  severe unipolar depression according to DSM-IV (SCID) und HAM-D (for patients)

          -  capable of giving informed consent

          -  negative pregnancy test (females)

        Exclusion Criteria:

          -  severe somatic illness

          -  psychiatric disorder (for healthy controls)

          -  an axis I comorbidity other than MDD , other than anxiety symptoms (for patients)

          -  clinically relevant alterations in blood draw, ecg, and somatic testing

          -  substance dependency disorder

          -  intake of psychopharmacological medication in last 6 months

          -  first degree relative with Axis 1 disorder (for Pilot I study)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rupert Lanzenberger, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry and Psychotherapy, Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rupert Lanzenberger, Prof.</last_name>
    <phone>014040035760</phone>
    <email>rupert.lanzenberger@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rupert Lanzenberger, A/Prof.</last_name>
      <phone>+43 40400</phone>
      <phone_ext>3825</phone_ext>
      <email>rupert.lanzenberger@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Rupert Lanzenberger, A/Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2016</study_first_posted>
  <last_update_submitted>August 18, 2017</last_update_submitted>
  <last_update_submitted_qc>August 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Rupert Lanzenberger</investigator_full_name>
    <investigator_title>Assoc. Prof. PD Dr. Rupert Lanzenberger, MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Serotonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

